A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II [a severe metabolic myopathy, Pompe disease (PD)] as the currently available therapy, replacement of the missing enzyme acid alpha-glucosidase, fails to reverse skeletal muscle pathology. PD, a paradigm for LSDs, is characterized by both lysosomal abnormality and dysfunctional autophagy. Here, we show that TFEB is a viable therapeutic target in PD: overexpression of TFEB in a new muscle cell culture system and in mouse models of the disease reduced glycogen load and lysosomal size, improved autophagosome processing, and alleviated excessive accumulation of autophagic vacuoles. Unexpectedly, the exocytosed vesicles were labelled with lysosomal and autophagosomal membrane markers, suggesting that TFEB induces exocytosis of autophagolysosomes. Furthermore, the effects of TFEB were almost abrogated in the setting of genetically suppressed autophagy, supporting the role of autophagy in TFEB-mediated cellular clearance.

Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease / Spampanato, C.; Feeney, E.; Li, L.; Cardone, M.; Lim, J. A.; Annunziata, Fabio; Zare, H.; Polishchuk, R.; Puertollano, R.; Parenti, Giancarlo; Ballabio, Andrea; Raben, N.. - In: EMBO MOLECULAR MEDICINE. - ISSN 1757-4684. - 5:(2013), pp. 691-706. [10.1002/emmm.201202176]

Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease

ANNUNZIATA, FABIO;PARENTI, GIANCARLO;BALLABIO, ANDREA;
2013

Abstract

A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II [a severe metabolic myopathy, Pompe disease (PD)] as the currently available therapy, replacement of the missing enzyme acid alpha-glucosidase, fails to reverse skeletal muscle pathology. PD, a paradigm for LSDs, is characterized by both lysosomal abnormality and dysfunctional autophagy. Here, we show that TFEB is a viable therapeutic target in PD: overexpression of TFEB in a new muscle cell culture system and in mouse models of the disease reduced glycogen load and lysosomal size, improved autophagosome processing, and alleviated excessive accumulation of autophagic vacuoles. Unexpectedly, the exocytosed vesicles were labelled with lysosomal and autophagosomal membrane markers, suggesting that TFEB induces exocytosis of autophagolysosomes. Furthermore, the effects of TFEB were almost abrogated in the setting of genetically suppressed autophagy, supporting the role of autophagy in TFEB-mediated cellular clearance.
2013
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease / Spampanato, C.; Feeney, E.; Li, L.; Cardone, M.; Lim, J. A.; Annunziata, Fabio; Zare, H.; Polishchuk, R.; Puertollano, R.; Parenti, Giancarlo; Ballabio, Andrea; Raben, N.. - In: EMBO MOLECULAR MEDICINE. - ISSN 1757-4684. - 5:(2013), pp. 691-706. [10.1002/emmm.201202176]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/559594
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 255
  • ???jsp.display-item.citation.isi??? 243
social impact